In humans, ICIs targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and the programmed death 1 (PD-1)/PD ligand 1(PD-L1) axis have demonstrated clinical activity in several cancers [82]. This evidence concerns the gene CTLA4 and cancer.